冠心病介入治疗后阿托伐他汀致疲乏现象分析  

Clinical analysis of atorvastatin-induced fatigue in patients following percutaneous coronary intervention

作　　者：姜东炬[1] 孙飞[1] 贾玉琳[1] 胡高频[1] 付荣[1] 王冬冬[1] 

机构地区：[1]解放军210医院心内科,辽宁大连116021

出　　处：《心脏杂志》2011年第2期238-240,共3页Chinese Heart Journal

摘　　要：目的:探讨阿托伐他汀在冠心病患者中疲乏发生率及对服药顺应性影响。方法:入选介入治疗的冠心病患者477例(A组)和药物治疗患者312例(B组)。观察两组疲乏发生率、疲乏程度、对服药顺应性影响等,检测服药后肌酸激酶(CK)、丙氨酸氨基转移酶(ALT)及低密度脂蛋白胆固醇(LDL-C)水平。结果:①两组患者的疲乏主要以轻度疲乏为主,A组的疲乏发生率明显高于B组,并且A组的疲乏发生率更多的发生在服药后0～3个月内;②调整阿托伐他汀类药物可以部分而不是全部缓解疲乏症状;③两组患者CK、ALT及LDL-C水平无明显差异,但重度疲乏患者CK浓度明显高于轻、中度疲乏患者。结论:阿托伐他汀钙片引起的疲乏以轻度疲乏为主,在接受介入治疗的患者中疲乏的发生率偏高。AIM： To investigate the incidence and degree of atorvastatin-induced fatigue in patients with coronary heart disease（CHD） and to study the impact of fatigue on medication compliance.METHODS： The incidence and degree of atorvastatin-induced fatigue and the impact of fatigue on medication compliance were investigated in 477 percutaneous coronary intervention（PCI）-treated CHD patients（group A） and 312 drug-treated CHD patients（group B）.The effect of drug dosage adjustment on fatigue alleviation was studied and the levels of creatine kinase（CK）,alanine aminotransferase（ALT） and low-density lipoprotein（LDL） after taking atorvastatin were measured.RESULTS： The incidence of atorvastatin-induced fatigue in group A was higher than in group B and fatigue mainly occurred within 0-3 months after medication in group A.Fatigue-related drug dosage adjustment was observed in both groups and the incidence of drug dosage adjustment due to mild fatigue was higher in group B.Dosage adjustment of atorvastatin alleviated the fatigue in some but not all patients.No significant difference was found in CK,ALT and LDL levels between groups,but CK level was higher in patients with severe fatigue than in patients with moderate or mild fatigue.CONCLUSION： Atorvastatin-induced fatigue is mainly mild and the incidence of fatigue was higher in patients with PCI.

关 键 词：阿托伐他汀 疲乏 冠状动脉疾病 

分 类 号：R541.4[医药卫生—心血管疾病] R972.6[医药卫生—内科学]